I. Zabalza

Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies

C. Porta, T. Buchler, S. Buti, 2022, Targeted Oncology.

Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.

C. Porta, F. Massari, U. de Giorgi, 2022, Clinical genitourinary cancer.

Statins and renal cell carcinoma: antitumor activity and influence on cancer risk and survival.

F. Massari, M. Santoni, E. Grande, 2022, Critical reviews in oncology/hematology.

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).

C. Porta, R. Montironi, O. Fiala, 2023, Clinical genitourinary cancer.

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.

C. Porta, O. Fiala, R. Chiari, 2023, Minerva urology and nephrology.

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

C. Porta, O. Fiala, R. Chiari, 2023, European urology oncology.

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

C. Porta, R. Montironi, O. Fiala, 2023, Targeted Oncology.

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

C. Porta, E. Lam, O. Fiala, 2023, Cancer Immunology, Immunotherapy.